Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019475690> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2019475690 endingPage "1385" @default.
- W2019475690 startingPage "1384" @default.
- W2019475690 abstract "AllergyVolume 64, Issue 9 p. 1384-1385 Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis K. Kontou-Fili, Corresponding Author K. Kontou-Fili *Chief Allergology DepartmentEuroclinic Hospital8 Fidippidou st. Athens 11526Hellas (Gr)AthensGreeceTel.: +30 2107774666; ++30 6932421516Fax: +30 2106010842Email: kontoufk@otenet.grSearch for more papers by this authorC. I. Filis, C. I. FilisSearch for more papers by this author K. Kontou-Fili, Corresponding Author K. Kontou-Fili *Chief Allergology DepartmentEuroclinic Hospital8 Fidippidou st. Athens 11526Hellas (Gr)AthensGreeceTel.: +30 2107774666; ++30 6932421516Fax: +30 2106010842Email: kontoufk@otenet.grSearch for more papers by this authorC. I. Filis, C. I. FilisSearch for more papers by this author First published: 14 September 2009 https://doi.org/10.1111/j.1398-9995.2009.02045.xCitations: 42 High Omalizumab dose, administered at strictly 30-day intervals, controls venom immunotherapy reactions in systemic mastocytosis. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume64, Issue9September 2009Pages 1384-1385 RelatedInformation" @default.
- W2019475690 created "2016-06-24" @default.
- W2019475690 creator A5005433688 @default.
- W2019475690 creator A5081428817 @default.
- W2019475690 date "2009-09-01" @default.
- W2019475690 modified "2023-10-12" @default.
- W2019475690 title "Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis" @default.
- W2019475690 cites W1520005604 @default.
- W2019475690 cites W1972370007 @default.
- W2019475690 cites W2054792936 @default.
- W2019475690 cites W2061452912 @default.
- W2019475690 cites W2062979062 @default.
- W2019475690 cites W2120901603 @default.
- W2019475690 doi "https://doi.org/10.1111/j.1398-9995.2009.02045.x" @default.
- W2019475690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19432937" @default.
- W2019475690 hasPublicationYear "2009" @default.
- W2019475690 type Work @default.
- W2019475690 sameAs 2019475690 @default.
- W2019475690 citedByCount "53" @default.
- W2019475690 countsByYear W20194756902012 @default.
- W2019475690 countsByYear W20194756902013 @default.
- W2019475690 countsByYear W20194756902014 @default.
- W2019475690 countsByYear W20194756902015 @default.
- W2019475690 countsByYear W20194756902016 @default.
- W2019475690 countsByYear W20194756902017 @default.
- W2019475690 countsByYear W20194756902018 @default.
- W2019475690 countsByYear W20194756902019 @default.
- W2019475690 countsByYear W20194756902021 @default.
- W2019475690 countsByYear W20194756902022 @default.
- W2019475690 countsByYear W20194756902023 @default.
- W2019475690 crossrefType "journal-article" @default.
- W2019475690 hasAuthorship W2019475690A5005433688 @default.
- W2019475690 hasAuthorship W2019475690A5081428817 @default.
- W2019475690 hasConcept C141105273 @default.
- W2019475690 hasConcept C159654299 @default.
- W2019475690 hasConcept C16005928 @default.
- W2019475690 hasConcept C161191863 @default.
- W2019475690 hasConcept C203014093 @default.
- W2019475690 hasConcept C2778564945 @default.
- W2019475690 hasConcept C2778805511 @default.
- W2019475690 hasConcept C2779726688 @default.
- W2019475690 hasConcept C2780581156 @default.
- W2019475690 hasConcept C41008148 @default.
- W2019475690 hasConcept C512399662 @default.
- W2019475690 hasConcept C71924100 @default.
- W2019475690 hasConceptScore W2019475690C141105273 @default.
- W2019475690 hasConceptScore W2019475690C159654299 @default.
- W2019475690 hasConceptScore W2019475690C16005928 @default.
- W2019475690 hasConceptScore W2019475690C161191863 @default.
- W2019475690 hasConceptScore W2019475690C203014093 @default.
- W2019475690 hasConceptScore W2019475690C2778564945 @default.
- W2019475690 hasConceptScore W2019475690C2778805511 @default.
- W2019475690 hasConceptScore W2019475690C2779726688 @default.
- W2019475690 hasConceptScore W2019475690C2780581156 @default.
- W2019475690 hasConceptScore W2019475690C41008148 @default.
- W2019475690 hasConceptScore W2019475690C512399662 @default.
- W2019475690 hasConceptScore W2019475690C71924100 @default.
- W2019475690 hasIssue "9" @default.
- W2019475690 hasLocation W20194756901 @default.
- W2019475690 hasLocation W20194756902 @default.
- W2019475690 hasOpenAccess W2019475690 @default.
- W2019475690 hasPrimaryLocation W20194756901 @default.
- W2019475690 hasRelatedWork W1787157457 @default.
- W2019475690 hasRelatedWork W2099005106 @default.
- W2019475690 hasRelatedWork W2136016974 @default.
- W2019475690 hasRelatedWork W2140994897 @default.
- W2019475690 hasRelatedWork W2214644174 @default.
- W2019475690 hasRelatedWork W2765484807 @default.
- W2019475690 hasRelatedWork W2766065491 @default.
- W2019475690 hasRelatedWork W2900203670 @default.
- W2019475690 hasRelatedWork W3086562705 @default.
- W2019475690 hasRelatedWork W2293053005 @default.
- W2019475690 hasVolume "64" @default.
- W2019475690 isParatext "false" @default.
- W2019475690 isRetracted "false" @default.
- W2019475690 magId "2019475690" @default.
- W2019475690 workType "article" @default.